Personalis Free Cash Flow 2018-2025 | PSNL
Personalis free cash flow from 2018 to 2025. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
| Personalis Annual Free Cash Flow | |
|---|---|
| 2024 | -46.51 |
| 2023 | -67.17 |
| 2022 | -120.13 |
| 2021 | -81.91 |
| 2020 | -45.90 |
| 2019 | -26.45 |
| 2018 | -2.28 |
| 2017 | -4.87 |
| Personalis Quarterly Free Cash Flow | |
|---|---|
| 2025-09-30 | -57.13 |
| 2025-06-30 | -33.70 |
| 2025-03-31 | -20.47 |
| 2024-12-31 | -46.51 |
| 2024-09-30 | -37.47 |
| 2024-06-30 | -31.03 |
| 2024-03-31 | -20.52 |
| 2023-12-31 | -67.17 |
| 2023-09-30 | -50.23 |
| 2023-06-30 | -32.68 |
| 2023-03-31 | -19.52 |
| 2022-12-31 | -120.13 |
| 2022-09-30 | -93.83 |
| 2022-06-30 | -57.65 |
| 2022-03-31 | -19.99 |
| 2021-12-31 | -81.91 |
| 2021-09-30 | -63.06 |
| 2021-06-30 | -42.22 |
| 2021-03-31 | -12.18 |
| 2020-12-31 | -45.90 |
| 2020-09-30 | -42.53 |
| 2020-06-30 | -24.85 |
| 2020-03-31 | -8.72 |
| 2019-12-31 | -26.45 |
| 2019-09-30 | -26.94 |
| 2019-06-30 | -13.64 |
| 2019-03-31 | -0.89 |
| 2018-12-31 | |
| 2018-09-30 | -4.81 |
| 2018-06-30 | -2.44 |
| 2017-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.615B | $0.085B |
| Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $27.493B | 9.29 |
| BridgeBio Pharma (BBIO) | United States | $11.909B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.238B | 16.62 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.580B | 21.61 |
| Bausch Health Cos (BHC) | Canada | $2.466B | 1.75 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.117B | 7.96 |
| Taysha Gene Therapies (TSHA) | United States | $1.049B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.239B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.085B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.017B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |